N0287

NNC 55-0396 hydrate

≥98% (HPLC)

• Synonym(e): (1S,2S)-2-(2-(N-[(3-Benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride hydrate, NNC55-0396
• Empirische Formel (Hill-System): C₃₀H₄₀Cl₂FN₃O₂ · xH₂O
• Molekulargewicht: 564.56 (anhydrous basis)
• MDL-Nummer: MFCD12910446
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 24278523
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: solid
• Lagerbedingungen: desiccated
• Farbe: white
• Löslichkeit: H₂O: >10 mg/mL
• Ersteller: Roche
• Lagertemp.: 2-8°C
• SMILES String: O.Cl.Cl.CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc3nc4ccccc4[nH]3)OC(=O)C5CC5
• InChI: 1S/C30H38FN3O2.2ClH.H2O/c1-20(2)28-24-13-12-23(31)19-22(24)14-15-30(28,36-29(35)21-10-11-21)16-18-34(3)17-6-9-27-32-25-7-4-5-8-26(25)33-27;;;/h4-5,7-8,12-13,19-21,28H,6,9-11,14-18H2,1-3H3,(H,32,33);2*1H;1H2/t28-,30-;;;/m0.../s1
• InChIKey: ICVIUVXDXJUZRQ-SHQDEPIZSA-N

Beschreibung

Biochem./physiol. Wirkung

NNC-55-0396 is a T-type calcium channel antagonists. It is the structural analog of mibefradil. NNC-55-0396 has the ability to block cell proliferation and stimulate cell apoptosis in leukemia cell lines.

Selective T-type calcium channel inhibitor

Leistungsmerkmale und Vorteile

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: Eyeshields, Gloves, type N95 (US)